EPIC-ND:一项多中心随机对照试验评估社会处方对神经发育障碍儿童及其父母/照护者未满足社会需求的有效性——研究方案
本研究在澳大利亚新南威尔士州三级儿科康复服务中心开展多中心随机对照试验,用标准化筛查工具识别存在未满足社会需求的神经发育障碍儿童父母/照护者,随机分为主动对照组(资源包自我导航)或社会处方干预组(资源包加社区联结员面对面支持),总样本量392例,主要结局为减少未满足社会需求的有效性。
要点
- 神经发育障碍儿童父母/照护者的未满足社会需求通过标准化筛查工具识别。
- 社会处方干预组接受社区联结员面对面支持加资源包,主动对照组仅接受资源包自我导航。
- 主要结局为干预减少未满足社会需求的有效性,总样本量392例。
核心结论
- 本研究旨在评估共同设计的社会处方项目解决神经发育障碍儿童及其父母/照护者未满足社会需求的有效性、成本效果与成本效用,以及其在医疗系统中的实施与转化。
研究设计与样本
- 在澳大利亚新南威尔士州三级儿科康复服务中心开展的多中心随机对照试验,总样本量392例。
- 标准化筛查工具识别报告一项或以上未满足社会需求并签署知情同意的父母/照护者进入随机分组。
- 参与者随机分配至主动对照组或社会处方干预组。
主要发现
- 主动对照组通过包含可解决未满足社会需求服务信息的资源包进行自我导航。
- 社会处方干预组在资源包基础上接受社区联结员面对面支持。
- 筛查工具、资源包和社会处方干预由脑性瘫痪儿童父母/照护者及其医疗专业人员共同设计。
关键数值与推荐
- 主要结局为干预减少未满足社会需求的有效性。
- 次要结局包括父母/照护者转介至支持服务及参与情况、自付费用、儿童/青少年及父母/照护者健康相关生活质量、父母/照护者心理困扰、儿童/青少年医院服务使用及急诊就诊。
- 试验注册号ACTRN12625000324415。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background The social determinants of health contribute to health inequities experienced by children with neurodisability and pose barriers to engaging with healthcare systems. At an individual level, adverse social determinants of health are experienced as unmet social needs (USNs), for example, housing insecurity and financial hardship. Emerging evidence supports social prescribing interventions that systematically identify USNs and refer families to services to address these needs. This study aims to evaluate the effectiveness of a co-designed social prescribing programme to address the USNs of children with neurodisability and their parents/carers, its cost-effectiveness and cost-utility, and implementation and translation across the healthcare system. Methods and analysis The study will be conducted at the tertiary Paediatric Rehabilitation Services in New South Wales, Australia. A standardised screening tool will identify parents/carers experiencing USNs. Parents/carers who report one or more USN and consent will be eligible to participate in the randomised controlled trial. Participants will be randomised to an active control group or social prescribing intervention group (total sample size=392). The active control group will receive self-navigation via a resource pack containing information about services that can address USNs. The social prescribing intervention group will receive in-person Community Linker support, in addition to the resource pack. The screening tool, resource pack, and social prescribing intervention were co-designed with parents/carers of children with cerebral palsy and their healthcare professionals. The primary outcome is the effectiveness of interventions in reducing USNs. Secondary outcomes include parent/carer referrals to and engagement with support services, out-of-pocket expenses, child/young person and parent/carer health-related quality of life, parent/carer psychological distress, and child/young person hospital service use and emergency department presentations. Trial registration number ACTRN12625000324415.
引用
- BMJ Paediatrics Open:EPIC-ND: a multi-site, randomised controlled trial evaluating the effectiveness of social prescribing for the unmet social needs of children with a neurodisability and their parent/carers - a study protocol
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。